Company intelligence / Profile preview

Protez Pharmaceuticals

Malvern, Pennsylvania, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Protez Pharmaceuticals' lead compound PZ-601, a carbapenem antibiotic, entered a 100-patient Phase II clinical trial in May 2008 to evaluate safety and efficacy in patients with complicated skin and skin structure infections. The company was acquired by Novartis shortly after beginning this trial.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesantibiotics
Industry: Biotech

Drug pipeline

1 asset

ganaxolone

Phase 2

Indications: Focal onset seizures, Fragile X Syndrome, Epilepsy

Partnerships

Dainippon Sumitomo Pharma Co., Ltd. (DSP) - licensing agreement in 2005 for PZ-601

Beyond the preview

Go deeper on Protez Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protez Pharmaceuticals.

Explore the full profile